The following is a list of the top 100 prescribed medicines by U.S. National Sales in Q3 2012. Figures include sales through both retail and hospital channels, listed by drug name and sales value in U.S. dollars.
| Rank |
Drug |
Sales ($000) |
|
|
| 1 |
Nexium
AstraZeneca Pharmaceuticals |
1,420,907 |
2.93% |
Stats |
| 2 |
Abilify
Otsuka Pharmaceutical Co. |
1,405,226 |
1.89% |
Stats |
3 ( 2) |
Crestor
AstraZeneca Pharmaceuticals |
1,245,527 |
10.74% |
Stats |
| 4 (2) |
Cymbalta
Eli Lilly and Company |
1,158,353 |
9.50% |
Stats |
| 5 (2) |
Humira
Abbott Laboratories |
1,152,261 |
13.45% |
Stats |
6 ( 2) |
Advair Diskus
GlaxoSmithKline |
1,148,611 |
2.10% |
Stats |
| 7 (1) |
Enbrel
Amgen Inc. |
1,066,697 |
12.51% |
Stats |
| 8 (2) |
Remicade
Centocor Ortho Biotech, Inc |
952,068 |
2.02% |
Stats |
| 9 (4) |
Copaxone
Teva Pharmaceuticals |
877,591 |
9.93% |
Stats |
| 10 (1) |
Neulasta
Amgen Inc. |
832,784 |
-1.17% |
Stats |
| 11 (1) |
Rituxan
Genentech, Inc |
773,460 |
-5.61% |
Stats |
| 12 (4) |
Atripla
Gilead Sciences, Inc. |
692,246 |
1.34% |
Stats |
| 13 (2) |
OxyContin
|
679,924 |
-0.55% |
Stats |
| 14 (3) |
Spiriva
Boehringer Ingelheim Pharmaceuticals, Inc |
669,882 |
1.31% |
Stats |
| 15 (4) |
Januvia
Merck & Co., Inc. |
651,299 |
7.50% |
Stats |
| 16 (2) |
Avastin
Genentech, Inc |
650,363 |
0.41% |
Stats |
| 17 (7) |
Lantus
Sanofi-Aventis |
556,147 |
4.94% |
Stats |
| 18 (5) |
Truvada
Gilead Sciences, Inc. |
551,280 |
1.56% |
Stats |
| 19 (7) |
Lantus Solostar
Sanofi-Aventis |
535,660 |
11.36% |
Stats |
| 20 (2) |
Epogen
Amgen Inc. |
526,118 |
-5.18% |
Stats |
| 21 (7) |
Lyrica
Pfizer Inc |
499,777 |
9.94% |
Stats |
| 22 (9) |
Celebrex
Pfizer Inc |
492,984 |
12.77% |
Stats |
| 23 (20) |
Singulair
Merck & Co., Inc. |
486,837 |
-62.20% |
Stats |
| 24 (1) |
Diovan
Novartis Corporation |
469,299 |
-4.29% |
Stats |
| 25 (9) |
Gleevec
Novartis Corporation |
454,935 |
10.57% |
Stats |
| 26 (4) |
Herceptin
Genentech, Inc |
450,251 |
-0.84% |
Stats |
| 27 (8) |
Namenda
Forest Pharmaceuticals, Inc |
432,634 |
6.05% |
Stats |
| 28 (14) |
Suboxone
Reckitt Benckiser Pharmaceuticals Inc. |
392,977 |
14.63% |
Stats |
| 29 (4) |
Avonex
Biogen Idec |
392,159 |
-5.34% |
Stats |
| 30 (3) |
enoxaparin
Generic |
388,188 |
-15.96% |
Stats |
| 31 (6) |
Lucentis
Genentech, Inc |
382,048 |
-1.88% |
Stats |
| 32 |
escitalopram
Generic |
381,081 |
-8.48% |
Stats |
| 33 (6) |
ONE TOUCH ULTRA
|
374,548 |
3.43% |
Stats |
| 34 (2) |
Diovan HCT
Novartis Corporation |
372,714 |
-7.39% |
Stats |
| 35 (3) |
Vyvanse
Shire US Inc |
365,023 |
-2.81% |
Stats |
| 36 (7) |
Zetia
Merck & Co., Inc. |
360,711 |
7.06% |
Stats |
| 37 (7) |
AndroGel
Abbott Laboratories |
347,674 |
6.38% |
Stats |
| 38 (3) |
methylphenidate
Generic |
346,945 |
0.01% |
Stats |
| 39 (18) |
Actos
Takeda Pharmaceuticals North America, Inc |
333,494 |
-41.96% |
Stats |
| 40 (5) |
Lidoderm
Endo Pharmaceuticals |
326,812 |
6.92% |
Stats |
| 41 (7) |
TriCor
Abbott Laboratories |
309,635 |
6.40% |
Stats |
| 42 (7) |
Rebif
|
308,352 |
8.88% |
Stats |
| 43 (3) |
Symbicort
AstraZeneca Pharmaceuticals |
307,678 |
4.37% |
Stats |
| 44 (10) |
Novolog
Novo Nordisk Inc. |
293,893 |
8.83% |
Stats |
| 45 (5) |
Incivek
Vertex Pharmaceuticals |
293,018 |
-18.72% |
Stats |
| 46 (9) |
Seroquel XR
AstraZeneca Pharmaceuticals |
284,299 |
6.05% |
Stats |
| 47 (3) |
Alimta
Eli Lilly and Company |
276,306 |
-1.39% |
Stats |
| 48 (8) |
Viagra
Pfizer Inc |
276,085 |
7.82% |
Stats |
| 49 (8) |
Levemir
Novo Nordisk Inc. |
274,892 |
7.66% |
Stats |
| 50 (1) |
amphetamine/dextroamphetamine
Generic |
272,504 |
-0.97% |
Stats |
| 51 (12) |
NovoLog FlexPen
Novo Nordisk Inc. |
270,735 |
11.89% |
Stats |
| 52 (12) |
ProAir HFA
Teva Pharmaceuticals |
267,692 |
12.06% |
Stats |
| 53 (7) |
Lovaza
GlaxoSmithKline |
266,568 |
8.82% |
Stats |
| 54 (1) |
Combivent
Boehringer Ingelheim Pharmaceuticals, Inc |
265,411 |
-1.79% |
Stats |
| 55 (22) |
Varivax
Merck & Co., Inc. |
263,952 |
31.34% |
Stats |
| 56 (3) |
Niaspan
Abbott Laboratories |
262,879 |
4.70% |
Stats |
| 57 (10) |
Procrit
Janssen Pharmaceuticals, Inc |
262,659 |
-10.20% |
Stats |
| 58 (8) |
Humalog
Eli Lilly and Company |
251,389 |
8.03% |
Stats |
| 59 (1) |
metoprolol
Generic |
249,769 |
-0.87% |
Stats |
| 60 (2) |
Neupogen
Amgen Inc. |
248,423 |
2.65% |
Stats |
| 61 (9) |
Nasonex
Merck & Co., Inc. |
247,294 |
-9.30% |
Stats |
| 62 (1) |
Flovent HFA
GlaxoSmithKline |
237,214 |
-2.46% |
Stats |
| 63 (2) |
Reyataz
Bristol-Myers Squibb Company |
236,127 |
1.20% |
Stats |
| 64 (4) |
Isentress
Merck & Co., Inc. |
233,391 |
2.58% |
Stats |
| 65 (6) |
Vytorin
Merck & Co., Inc. |
228,895 |
6.33% |
Stats |
| 66 (1) |
modafinil
Generic |
228,428 |
-0.79% |
Stats |
| 67 (3) |
Janumet
Merck & Co., Inc. |
228,307 |
5.21% |
Stats |
| 68 (5) |
Cialis
Eli Lilly and Company |
226,446 |
9.05% |
Stats |
| 69 (14) |
acetaminophen/hydrocodone
Generic |
226,379 |
18.96% |
Stats |
| 70 (17) |
Gilenya
Novartis Corporation |
221,299 |
21.19% |
Stats |
| 71 (2) |
Aranesp
Amgen Inc. |
219,796 |
-1.51% |
Stats |
| 72 (3) |
Restasis
Allergan, Inc |
217,097 |
7.35% |
Stats |
| 73 (6) |
Aciphex
Eisai Corporation |
215,681 |
10.07% |
Stats |
| 74 (24) |
Victoza
Novo Nordisk Inc. |
209,163 |
27.22% |
Stats |
| 75 (1) |
Pradaxa
Boehringer Ingelheim Pharmaceuticals, Inc |
209,063 |
3.84% |
Stats |
| 76 (6) |
Orencia
Bristol-Myers Squibb Company |
203,359 |
6.17% |
Stats |
| 77 (11) |
Betaseron
Bayer Healthcare Pharmaceuticals |
203,170 |
11.98% |
Stats |
| 78 (49) |
Eloxatin
Sanofi-Aventis |
203,067 |
-55.33% |
Stats |
| 79 (7) |
VESIcare
Astellas Pharma US |
201,552 |
9.64% |
Stats |
| 80 (10) |
Dexilant
Takeda Pharmaceuticals North America, Inc |
200,149 |
13.25% |
Stats |
| 81 (9) |
Adderall XR
Shire US Inc |
197,947 |
-7.81% |
Stats |
| 82 (4) |
fentanyl
Generic |
196,777 |
-0.39% |
Stats |
| 83 (3) |
Prezista
Janssen Pharmaceuticals, Inc |
196,751 |
1.17% |
Stats |
84 ( ) |
Zostavax
|
194,633 |
 |
Stats |
| 85 (7) |
Evista
Eli Lilly and Company |
189,378 |
9.53% |
Stats |
| 86 (7) |
Benicar
Daiichi Sankyo |
188,980 |
9.67% |
Stats |
| 87 () |
Gardasil
|
188,952 |
|
Stats |
| 88 (68) |
Lipitor
Pfizer Inc |
186,508 |
-67.80% |
Stats |
| 89 (8) |
budesonide
Generic |
186,479 |
-3.36% |
Stats |
| 90 (7) |
Synthroid
Abbott Laboratories |
185,868 |
12.61% |
Stats |
| 91 () |
Xolair
|
184,317 |
|
Stats |
| 92 (2) |
Renvela
Genzyme Corporation |
183,699 |
7.39% |
Stats |
| 93 (4) |
Lunesta
Sunovion Pharmaceuticals Inc. |
183,190 |
2.23% |
Stats |
| 94 (10) |
Prevnar 13
Wyeth |
177,527 |
-5.86% |
Stats |
| 95 (1) |
Xeloda
Roche Pharmaceuticals |
176,414 |
5.28% |
Stats |
| 96 () |
EpiPen 2-Pak
|
174,048 |
|
Stats |
| 97 () |
Sensipar
Amgen Inc. |
172,317 |
|
Stats |
| 98 (7) |
Zyvox
Pfizer Inc |
171,755 |
-1.37% |
Stats |
| 99 (85) |
atorvastatin
Generic |
170,506 |
-78.25% |
Stats |
| 100 () |
Stelara
|
169,648 |
|
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
2)
2)
)
